Search Results

KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that Key Biotec, a division of Key Capital, has entered into agreement with Immunitor group interests (“Immunitor”) to exclusively license its breakthrough and patented oral tableted platform vaccine and immunotherapeutic products for North, Central and South America (excluding Canada), the EU (excluding UK), Australia and New Zealand (the “Territory”).

Multiple Human Clinical Trials Have Demonstrated Unprecedented Success in Cancers, Including HCC Liver Cancer, Vascular and Other Diseases, and Viruses

KEY CAPITAL CORPORATION advises that Immunitor, its Licensing partner, continues to receive favorable reports from people in Asian and African countries using the Immunitor HAP-V+ Immune Supplement in cases of respiratory infections.

KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that in association with Immunitor Inc, the Company will seek to fast-track further clinical studies and regulatory approval of the FDA Orphan Drug Designated Immunitor V5 as a development priority. Immunitor V5 has demonstrated unparalleled success in all clinical studies to date for the treatment of liver cancer, which is p

Patented Immunitor Oral Pill Platform Intellectual Property Optimizes M.Vaccae Supplement and Ionic Magnesium Delivery to Immune System

KEY CAPITAL CORPORATION advises that it continues to work with Immunitor, its partner and Licensor, to progress further research and development of its breakthrough therapeutic vaccines, and for several unique supplements.

KEY CAPITAL CORPORATION advises that the Company, through Key Biotec, is offering an unique opportunity to major investors, institutions, and/or government agencies to partner a patent protected oral pill COVID-19 therapeutic vaccine that has been developed by the Immunitor scientific team, and subject to clinical validation and regulatory approvals, is market ready and able to support an urgent global need.